OncoMyx Announces Exclusive Option to License Intellectual Property Rights for Myxoma Virus Technology from University of Florida
OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, has extended its intellectual property (IP) portfolio to include an exclusive option to license IP rights for the use and delivery of myxoma virus to treat certain cancers from the University of Florida Research Foundation (UFRF). This IP was developed by OncoMyx cofounder Grant McFadden, Ph.D., and his collaborators, when he was a Professor at the University of Florida College of Medicine.
“We are pleased to enter this licensing agreement with OncoMyx, the leading company for multi-armed systemic delivery in oncology and hematology,” said Christopher Cogle, Professor of Medicine at the University of Florida and a Leukemia & Lymphoma Society Clinical Research Scholar. “As practicing oncologists in blood cancer clinics, we struggle to find effective treatments for our patients. The myxoma virus technology has tremendous potential to help our patients suffering from multiple myeloma, AML, myelofibrosis, lymphomas, and other blood conditions, such as graft versus host disease. Rather than using single mechanism agents, myxoma therapy combines multiple arming strategies delivered concurrently to ignite the immune system – establishing a new treatment paradigm in blood cancers.”
Learn more about OncoMyx Announces Exclusive Option to License Intellectual Property Rights for Myxoma Virus Technology from University of Florida.